{"id":107052,"date":"2025-05-16T19:21:09","date_gmt":"2025-05-16T19:21:09","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/107052\/"},"modified":"2025-05-16T19:21:09","modified_gmt":"2025-05-16T19:21:09","slug":"rapid-rx-quiz-dangerous-drug-interactions","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/107052\/","title":{"rendered":"Rapid Rx Quiz: Dangerous Drug Interactions"},"content":{"rendered":"<p>Relugolix when co-administered with P-glycoprotein inhibitors is <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38720547\/\" target=\"_blank\" rel=\"noopener\">associated<\/a> with the highest risk for drug-drug interactions in patients with prostate cancer. Relugolix is a gonadotropin-releasing hormone antagonist that is significantly affected by P-glycoprotein inhibitors, which increase its plasma levels. Co-administration with P-glycoprotein and strong CYP3A inducers also reduces the efficacy of relugolix. These factors make relugolix particularly prone to clinically significant drug-drug interactions when combined with commonly used drugs.<\/p>\n<p>Although flutamide can interact with warfarin, requiring monitoring and possible dose adjustments, these interactions are relatively well-characterized and manageable. The level of interaction risk is not as severe or broad as that of relugolix with P-glycoprotein inhibitors.<\/p>\n<p>Bicalutamide has some drug-drug interaction potential owing to CYP3A4 inhibition and protein-binding displacement effects, but these are not as extensive or complex as those seen with relugolix. Triptorelin is a luteinizing hormone\u2013releasing hormone agonist and, like others in this class, is not known to cause significant drug-drug interactions. Bicalutamide and triptorelin have been used in combination with androgen deprivation therapy and have not been reported to have high drug-drug interaction rates.<\/p>\n<p> <a href=\"https:\/\/emedicine.medscape.com\/article\/2007095-overview\" target=\"_blank\" rel=\"noopener\">Learn more<\/a> about prostate cancer treatment.<\/p>\n<p>Medscape\u00a0\u00a9\u00a02025\u00a0WebMD, LLC<\/p>\n<p xmlns:dctm=\"https:\/\/www.documentum.com\" xmlns:fmt=\"https:\/\/java.sun.com\/jstl\/fmt\" xmlns:jsp=\"jsp\">Any views expressed above are the author&#8217;s own and do not necessarily reflect the views of WebMD or Medscape.<\/p>\n<p id=\"citation\">\n       Cite this: Mary L. Windle.\u00a0Rapid Rx Quiz: Dangerous Drug Interactions\u00a0&#8211;\u00a0Medscape\u00a0&#8211;\u00a0May\u00a016,\u00a02025.<\/p>\n","protected":false},"excerpt":{"rendered":"Relugolix when co-administered with P-glycoprotein inhibitors is associated with the highest risk for drug-drug interactions in patients with&hellip;\n","protected":false},"author":2,"featured_media":107053,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[48999,49000,48989,48990,12303,1204,48997,27471,48994,6983,6982,105,48992,48991,27470,48996,4326,48998,1549,8200,48993,8427,48995,6984,14068,16,15],"class_list":{"0":"post-107052","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-af-atrial-fibrillation","9":"tag-anticoagulation-th","10":"tag-antiplatelet-agent","11":"tag-aspirin","12":"tag-atrial-fibrillation","13":"tag-cancer","14":"tag-cancer-prostate","15":"tag-carcinoma","16":"tag-drug-interactions","17":"tag-fellows","18":"tag-fellowship","19":"tag-health","20":"tag-lmwh-low-molecular-weight-heparin","21":"tag-low-molecular-weight-heparin","22":"tag-malignant-neoplasia","23":"tag-malignant-prostate-neoplasm","24":"tag-medication","25":"tag-metabolic","26":"tag-metabolism","27":"tag-patient-safety","28":"tag-phenytoin-toxicity","29":"tag-prostate-cancer","30":"tag-prostate-carcinoma","31":"tag-residency","32":"tag-thromboembolism","33":"tag-uk","34":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114519139066065350","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/107052","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=107052"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/107052\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/107053"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=107052"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=107052"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=107052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}